A New Score for Estimating Survival After Definitive Radiochemotherapy of Limited Disease Small Cell Lung Cancers
Authors:
- 2 May 2016
- journal article
- research article
- Published by Springer Nature in Lung
- Vol. 194 (4) , 625-629
Abstract
Most patients with limited disease small cell lung cancer (LD-SCLC) receive definitive radiochemotherapy. Some patients cannot withstand combined modality treatments. Patients with short life expectancies should receive less time-consuming programs. For patients with favorable prognoses, cure while avoiding late toxicity is important. Personalized treatment programs are required. An instrument to estimate the survival after radiochemotherapy of LD-SCLC was created.Keywords
This publication has 15 references indexed in Scilit:
- Older patients with inoperable non-small cell lung cancerStrahlentherapie und Onkologie, 2014
- Comparison of Once and Twice Daily Radiotherapy for Limited Stage Small-Cell Lung CancerLung, 2013
- The first survival score for patients with brain metastases from small cell lung cancer (SCLC)Clinical Neurology and Neurosurgery, 2013
- A validated survival score for patients with metastatic spinal cord compression from non-small cell lung cancerBMC Cancer, 2012
- Limited-Disease Small-Cell Lung Cancer2011
- Prognostic factors differ by tumor stage for small cell lung cancerCancer, 2009
- Treatment Resistance of Solid TumorsMedical Oncology, 2001
- Radiosurgery for brain metastases: a score index for predicting prognosisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000
- Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and EtoposideNew England Journal of Medicine, 1999
- Scoring System for the Preoperative Evaluation of Metastatic Spine Tumor PrognosisSpine, 1990